Spatial architecture shapes programmed cell death-associated immune niches and therapeutic resistance in clear cell renal cell carcinoma
- 1Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
Abstract
Clear cell renal cell carcinoma (ccRCC) is characterized by VHL-HIF pathway alterations, lipid remodeling, abnormal angiogenesis, and marked immune heterogeneity. These features create a highly vascular yet unevenly perfused microenvironment in which vascular dysfunction, hypoxia, stromal barriers, and myeloid clearance influence whether cell death becomes immunologically productive. Although immune checkpoint inhibitor combinations, vascular endothelial growth factor receptor tyrosine kinase inhibitors, and HIF-2α inhibitors have improved outcomes, primary and acquired resistance and discordant responses among lesions remain common. Bulk PD-L1 expression, immune-cell abundance, and cell-death-related transcript signatures do not resolve this heterogeneity. Following current nomenclature, regulated cell death (RCD) is the mechanistically preferred umbrella term; we retain programmed cell death (PCD) in the conceptual label because it remains widely used in the RCC oncology literature, while requiring RCD execution-level evidence for mechanistic claims. Single-cell and spatial multi-omics studies increasingly show that the identity of the dying cell, execution of the death program, accessibility of death-derived material, and the recipient immune cells operate as a coupled local system. We define a PCD-associated immune niche as a spatial tissue state in which representative, non-exclusive immune-routing axes can direct tumor-cell death toward cDC1-mediated cross-presentation and adaptive antitumor immunity, TAM-dominant efferocytosis and tissue repair, or intermediate mixed states. This Review focuses predominantly on ccRCC, evaluates ferroptosis, apoptosis, pyroptosis, necroptosis, and PANoptosis, and briefly considers emerging RCD modalities for which ccRCC evidence is less mature. We further propose composite spatial biomarkers and mechanism-guided combinations that link cellular source, execution evidence, immune routing, and clinical outcome.
Related
- CD36-Mediated Lipid Metabolic Reprogramming in Hepatocellular Carcinoma: Crosstalk With Immunity, Ferroptosis, and Therapeutic Resistance.
- REDD1 in Clear Cell Renal Cell Carcinoma: Linking Stress Adaptation, Proteostasis and Therapeutic Resistance
- The CYB5R3–mARC1 Redox Axis in Metabolic Dysfunction-associated Steatotic Liver Disease: Mechanistic Basis and Therapeutic Prospects across the Steatosis–Cirrhosis–Hepatocellular Carcinoma Spectrum
- Portal Vein Tumor Thrombus in Hepatocellular Carcinoma: An Immune Sanctuary Driving Immune Exclusion and Therapeutic Resistance.
- Decoding the role of cancer-associated fibroblasts in cisplatin resistance of head and neck squamous cell carcinoma
BibTeX
@article{yin2026spatial,
title = {{Spatial architecture shapes programmed cell death-associated immune niches and therapeutic resistance in clear cell renal cell carcinoma}},
author = {Yu Yin and Junlong Wang and Dengxiong Li and Dandan Qiu},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1952158},
url = {https://doi.org/10.3389/fonc.2026.1952158},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Spatial architecture shapes programmed cell death-associated immune niches and therapeutic resistance in clear cell renal cell carcinoma
AU - Yu Yin
AU - Junlong Wang
AU - Dengxiong Li
AU - Dandan Qiu
PY - 2026
DA - 2026/10/12
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1952158
UR - https://doi.org/10.3389/fonc.2026.1952158
AB - Clear cell renal cell carcinoma (ccRCC) is characterized by VHL-HIF pathway alterations, lipid remodeling, abnormal angiogenesis, and marked immune heterogeneity. These features create a highly vascular yet unevenly perfused microenvironment in which vascular dysfunction, hypoxia, stromal barriers, and myeloid clearance influence whether cell death becomes immunologically productive. Although immune checkpoint inhibitor combinations, vascular endothelial growth factor receptor tyrosine kinase inhibitors, and HIF-2α inhibitors have improved outcomes, primary and acquired resistance and discordant responses among lesions remain common. Bulk PD-L1 expression, immune-cell abundance, and cell-death-related transcript signatures do not resolve this heterogeneity. Following current nomenclature, regulated cell death (RCD) is the mechanistically preferred umbrella term; we retain programmed cell death (PCD) in the conceptual label because it remains widely used in the RCC oncology literature, while requiring RCD execution-level evidence for mechanistic claims. Single-cell and spatial multi-omics studies increasingly show that the identity of the dying cell, execution of the death program, accessibility of death-derived material, and the recipient immune cells operate as a coupled local system. We define a PCD-associated immune niche as a spatial tissue state in which representative, non-exclusive immune-routing axes can direct tumor-cell death toward cDC1-mediated cross-presentation and adaptive antitumor immunity, TAM-dominant efferocytosis and tissue repair, or intermediate mixed states. This Review focuses predominantly on ccRCC, evaluates ferroptosis, apoptosis, pyroptosis, necroptosis, and PANoptosis, and briefly considers emerging RCD modalities for which ccRCC evidence is less mature. We further propose composite spatial biomarkers and mechanism-guided combinations that link cellular source, execution evidence, immune routing, and clinical outcome.
SN - 2234-943X
ER -